CpG oligodeoxynucleotide stimulates protective innate immunity against human renal cell carcinoma xenografted in nude mice

Journal of Immunotherapy

Volumn 34, Issue 7, 2011, Pages 535-541

  Zhou, Pei Jun ^a   Ma, Bin Bin ^a   He, Wei ^a   Xu, Da ^a   Wang, Xiang Hui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

CpG oligodeoxynucleotides; immunotherapy; innate immunity; mice; renal cell carcinoma

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDE 1826; INTERLEUKIN 12; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN TISSUE; INNATE IMMUNITY; KIDNEY CARCINOMA; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL TIME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CARCINOMA, RENAL CELL; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-12; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; MICE, NUDE; OLIGODEOXYRIBONUCLEOTIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80051550272     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3182272ecf     Document Type: Article

References (43)

1. Gupta K, Miller JD, Li JZ, et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34:193-205.
2. Rini BI, Campbell SC, Rathmell WK. Renal cell carcinoma. Curr Opin Oncol. 2006;18:289-296. (Pubitemid 43740426)
3. Ramsey S, Aitchison M. Treatment for renal cancer: are we beyond the cytokine era? Nat Clin Pract Urol. 2006;3:478-484. (Pubitemid 44377538)
4. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356: 125-134. (Pubitemid 46089673)
5. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124. (Pubitemid 46089672)
6. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374:546-549.
7. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709-760. (Pubitemid 34293438)
8. Jahrsdö rfer B, Weiner GJ. CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther. 2008;3:27-32. (Pubitemid 351410539)
9. Houot R, Levy R. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood. 2009;113:3546-3552.
10. Kim HA, Ko HM, Ju HW, et al. CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells. Cancer Lett. 2009;274:160-164.
11. Murad YM, Clay TM. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer. BioDrugs. 2009;23: 361-375.
12. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 2008;27:161-167.
13. Tripp CH, Ebner S, Ratzinger G, et al. Conditioning of the injection site with CpG enhances the migration of adoptively transferred dendritic cells and endogenous CD8+ T-cell responses. J Immunother. 2010;33:115-125.
14. Ishizaki H, Song GY, Srivastava T, et al. Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression. J Immunother. 2010;33:609-617.
15. Mangsbo SM, Sandin LC, Anger K, et al. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother. 2010;33:225-235.
16. Goforth R, Salem AK, Zhu X, et al. Immune stimulatory antigen loaded particles combined with depletion of regulatory T cells induce potent tumor specific immunity in a mouse model of melanoma. Cancer Immunol Immunother. 2009;58: 517-530.
17. Betting DJ, Yamada RE, Kafi K, et al. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma. J Immunother. 2009;32:622-631.
18. Ginzkey C, Eicker SO, Marget M, et al. Increase in tumor size following intratumoral injection of immunostimulatory CpGcontaining oligonucleotides in a rat glioma model. Cancer Immunol Immunother. 2010;59:541-551.
19. Arase H, Saito T, Phillips JH, et al. Cutting edge: the mouse NK cell-associated antigen recognized by DX5 monoclonal antibody is CD49b (alpha 2 integrin, very late antigen-2). J Immunol. 2001;167:1141-1144. (Pubitemid 32703106)
20. Schrader AJ, Varga Z, Hegele A, et al. Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches. J Cancer Res Clin Oncol. 2006;132:137-149. (Pubitemid 43015774)
21. Van Poppel H, Joniau S, Van Gool SW. Vaccine Therapy in Patients with Renal Cell Carcinoma. Eur Urol. 2009;55: 1333-1342.
22. Fujii H, Trudeau JD, Teachey DT, et al. In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides. Blood. 2007;109:2008-2013. (Pubitemid 46348200)
23. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest. 2007;117:1184-1194. (Pubitemid 46718403)
24. Mangsbo SM, Ninalga C, Essand M, et al. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+T-cell immunity. J Immunother. 2008;31:34-42. (Pubitemid 351619402)
25. Lubaroff DM, Karan D. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer. Adv Drug Deliv Rev. 2009;61:268-274.
26. Chagnon F, Tanguay S, Ozdal OL, et al. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides. Clin Cancer Res. 2005;11:1302-1311. (Pubitemid 40175784)
27. VanOosten RL, Griffith TS. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy. Cancer Res. 2007;67:11980-11990.
28. Buhtoiarov IN, Sondel PM, Eickhoff JC, et al. Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides. Immunology. 2006;120:412-423. (Pubitemid 46232916)
29. McDermott-Lancaster RD, Ito T, Kohaska K, et al. The nude mouse-characteristics, breeding and husbandry. Int J Lepr Other Mycobact Dis. 1987;55:885-888.
30. De Cesare M, Calcaterra C, Pratesi G, et al. Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy. Clin Cancer Res. 2008;14:5512-5518.
31. Ballas ZK, Krieg AM, Warren T, et al. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol. 2001;167:4878-4886. (Pubitemid 33009716)
32. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol. 2001; 2:293-299. (Pubitemid 33706339)
33. Krieg AM, Efler SM, Wittpoth M, et al. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucle-otide TLR9 agonist. J Immunother. 2004;27:460-471. (Pubitemid 39447354)
34. Wright SC, Bonavida B. YAC-1 variant clones selected for resistance to natural killer cytotoxic factors are also resistant to natural killer cell-mediated cytotoxicity. Proc Natl Acad Sci USA. 1983;80:1688-1692. (Pubitemid 13052474)
35. Ottenhof PC, Morales A, Baines MG. Quantitation of a whole blood assay for human natural killer cell activity. J Immunol Methods. 1981;42:305-318. (Pubitemid 11100868)
36. Goldfarb Y, Benish M, Rosenne E, et al. CpG-C oligodeoxynucleotides limit the deleterious effects of beta-adrenoceptor stimulation on NK cytotoxicity and metastatic dissemination. J Immunother. 2009;32:280-291.
37. Liu C, Yu S, Kappes J, et al. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumorbearing host. Blood. 2007;109:4336-4342. (Pubitemid 46743401)
38. Ballas ZK. Modulation of NK cell activity by CpG oligodeoxynucleotides. Immunol Res. 2007;39:15-21. (Pubitemid 47574882)
39. Gerosa F, Gobbi A, Zorzi P, et al. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol. 2005;174:727-734. (Pubitemid 40094266)
40. Fernandez NC, Lozier A, Flament C, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med. 1999;5: 405-411. (Pubitemid 29180578)
41. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3: 133-146. (Pubitemid 37328691)
42. De Cesare M, Sfondrini L, Campiglio M, et al. Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN. J Immunother. 2010;33:8-15.
43. Pillarisetty VG, Katz SC, Bleier JI, et al. Natural killer dendritic cells have both antigen presenting and lytic function and in response to CpG produce IFN-gamma via autocrine IL-12. J Immunol. 2005;174:2612-2618. (Pubitemid 40279674)